Nadia Tosti
Basel, BS 4070, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 09, 2026
Erratum to 'Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100815].
Journal: JTO clinical and research reports
Published: June 19, 2025
Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC.
Journal: JTO clinical and research reports
Published: November 21, 2024
Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 29, 2024
Corrigendum to 'IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications': [Annals of Oncology 34 (2023) p693-702].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 09, 2024
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 27, 2023
The role of HMGA1 protein in gastroenteropancreatic neuroendocrine tumors.
Journal: Cell cycle (Georgetown, Tex.)
Published: March 14, 2022
Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.
Journal: Breast (Edinburgh, Scotland)
Published: September 07, 2021
Nestin and CD34 expression in colorectal cancer predicts improved overall survival.
Journal: Acta oncologica (Stockholm, Sweden)
Published: March 18, 2021
Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Journal: Clinical pharmacology in drug development
Published: November 13, 2020
Transcriptional Enhancer Factor Domain Family member 4 Exerts an Oncogenic Role in Hepatocellular Carcinoma by Hippo-Independent Regulation of Heat Shock Protein 70 Family Members.
Journal: Hepatology communications
Published: September 09, 2020
Corrigendum to "HMGA1 expression in human hepatocellular carcinoma correlates with poor prognosis and promotes tumor growth and migration in in vitro models" [Neoplasia 18 (2016) 724-731].
Journal: Neoplasia (New York, N.Y.)
Published: May 22, 2020
Last Updated: 09/26/2026